<?xml version="1.0" encoding="UTF-8"?>
<p id="Par26">Prophylaxis with low-molecular-weight heparin (LMWH) is recommended for every patient, if not contraindicated [
 <xref ref-type="bibr" rid="CR72">72</xref>]. In a study involving 449 patients with severe COVID-19, anticoagulant therapy, mainly with LMWH, was associated with lower mortality in patients with markedly elevated D-dimer [
 <xref ref-type="bibr" rid="CR75">75</xref>]. The use of unfractionated heparin may be superior in critically ill patients with underlying renal failure, which is a contraindication to LMWH. Interestingly, in vivo models of coronavirus infection have shown that administration of unfractionated heparin functions as a decoy receptor, reducing viral infectivity and potentially augmenting viral clearance [
 <xref ref-type="bibr" rid="CR76">76</xref>]. Heparin also has anti-inflammatory effects, reduces myocardial inflammation, and has shown antiviral effects in animal models [
 <xref ref-type="bibr" rid="CR77">77</xref>]. Tissue plasminogen activator (TPA) has shown transient improvement in a case series but there is still a lack of data regarding the safety of use in this setting. Furthermore, there have been no data on the adequate dose of TPA [
 <xref ref-type="bibr" rid="CR78">78</xref>].
</p>
